We are live on ! Find out more
KLRS icon

Kalaris Therapeutics

85 hedge funds and large institutions have $294M invested in Kalaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,436% more capital inflows, than outflows

Capital inflows: $66.9M | Capital outflows: $4.36M

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

48% more call options, than puts

Call options by funds: $267K | Put options by funds: $180K

1% more funds holding

Funds holding: 84 → 85 (+1)

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

2.96% less ownership

Funds ownership: 42.96% → 40% (-3%)

Holders
85
Holders Change
+1
Holders Change %
+1.19%
% of All Funds
1.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
33
Reduced
21
Closed
17
Calls
$267​K
Puts
$180​K
Net Calls
+$87​K
Net Calls Change
-⁠$42​K

KLRS Hedge Fund Activity: Q3 2022 in Review

85 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2022, worth a combined $294M — up 168% from $110M a quarter earlier.

Fund positioning in KLRS was balanced in Q3 2022: 17 funds opened new positions, 17 closed out, 33 added to existing stakes and 21 trimmed.

The largest buyer was Artal Group, adding an estimated $22M. The largest seller was JP Morgan Chase, cutting an estimated $1.13M.

  • 85 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2022, up from 84 in Q2 2022.
  • Funds reported $294M of Kalaris Therapeutics stock for Q3 2022, up 168% quarter-over-quarter.
  • 17 funds opened new Kalaris Therapeutics positions in Q3 2022 and 17 closed out, a net change of 0 holders.
  • The largest Kalaris Therapeutics buyer in Q3 2022 was Artal Group, an estimated $22M added.
  • The largest Kalaris Therapeutics seller in Q3 2022 was JP Morgan Chase, an estimated $1.13M sold.

Based on aggregated 13F filings for Q3 2022.